The clinical implications of new oral anticoagulants: Will the potential advantages be achieved?

Thrombosis and Haemostasis

Volumn 103, Issue 1, 2010, Pages 34-39

  Phillips, Katherine W ^a   Ansell, Jack ^b  

^a BOSTON MEDICAL CENTER   (United States)

^b LENOX HILL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; GLYCOPROTEIN P INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROTON PUMP INHIBITOR; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; EMBOLISM; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; STROKE; THROMBOEMBOLISM; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; FACTOR XA; HEMORRHAGE; HUMANS; PROTHROMBIN; RISK ASSESSMENT; VITAMIN K;

EID: 74249107395     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-06-0361     Document Type: Review

References (37)

1. Ansell, J, et al. The pharmacology and management of the vitamin K antagonists: ACCP evidence-based clinical practice guidelines. Chest 2008; 133: 160S-198S.
2. Budnitz DS, et al. National surveillance of emergency department visits for outpatient adverse drug events. J Am Med Assoc 2006; 296: 1858-1866.
3. Santell JP, et al. Top 10 drug products involved in medication errors. Available at: www.usp.org/pdf/EN/patientSafety/drugSafetyReview2003-12-08.pdf
4. Weitz JI, et al. New Antithrombotic Drugs. Chest 2008; 133: 234S-256S.
5. Eriksson BI, et al. Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Developtment. Clin Pharmacokinet 2009; 48: 1-22.
6. Agnelli G, et al. ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116: 180-187.
7. Spyropoulos AC. Brave new world: The current and future use of novel anticoagulants. Thromb Res 2008; 123: 29-35.
8. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 2003; 362: 1691-1698.
9. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. J Am Med Assoc 2005; 293: 690-698.
10. Fiessinger JN, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. J Am Med Assoc 2005; 293: 681-689.
11. Wallentin L, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ES-TEEM randomized controlled trial. Lancet 2003; 362: 789-797.
12. RE-MODEL Study Group: Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185.
13. RE-NOVATE Study Group: Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
14. RE-MOBILIZE Writing Committee: Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor Dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9.
15. Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
16. RECORD1 Study Group: Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
17. RECORD2 Investigators: Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet 2008; 372: 31-39.
18. RECORD3 Investigators: Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
19. Turpie AGG, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomized trial. Lancet 2009; 373: 1673-1680.
20. Turpie AGG, et al. A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopedic surgery: effect on symptomatic venous thromboembolism, death, and bleeding. Blood (ASH Annual Meeting Abstracts) 2008; 112: 18-19 (Abstract 36).
21. Lassen M, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
22. Lassen MR, et al. The ADVANCE 2 study: A randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement. J Thromb Haemost 2009; 7 (Suppl. 2): Abstract #LB-MO-005.
23. Blech S, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-399.
24. Kubitza D, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939- an oral, direct Factor Xa inhibitor- after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880.
25. Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96: 274-284.
26. Stangier J, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
27. Shantsila E, Lip GY. Apixaban, an oral, direct inhibitor of activated Factor Xa. Curr Opin Investig Drugs 2008; 9: 1020-1033.
28. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295.
29. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008; 28: 380-386.
30. DiMatteo MR, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40: 794-811.
31. Cramer JA. Partial medication compliance: the enigma in poor medical outcomes. Am J Manag Care 1995; 1: 167-174.
32. Sullivan SD, et al. Noncompliance with medication regimens and subsequent hospitalizations: a literature analysis and cost of hospitalization estimate. J Res Pharm Econ 1990; 2: 19-33.
33. Dunbar-Jacob J, et al. Adherence in chronic disease. In : Annual review of nursing research. New York: Springer 2000; 18: pp. 48-90.
34. Platt AB, et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmcoepidemiology Drug Safety 2008; 17: 853-860.
35. Ansell JE. Optimizing the Efficacy and Safety of Oral Anticoagulant Therapy: High Quality Dose Management, Anticoagulation Clinics, and Patient Self-Management. Semin Vas Med 2003; 3: 261-269.
36. Kimmel SE, et al. The Influence of Patient Adherence on Anticoagulation Control with Warfarin : Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med 2007; 167: 229-235.
37. Fox M, et al. Cash-strapped US Patients may be skipping drugs. Reuters. 2/10/09. http://www.reuters.com/article/healthNews/idUSTRE5196SR20090211. Accessed on 2/11/09.